韩国2型糖尿病的20万成年人发现,与DPP-4抑制剂相比,SGLT-2抑制剂的痴呆症风险降低了35%。 200,000 adults with type 2 diabetes in South Korea found a 35% reduced dementia risk with SGLT-2 inhibitors compared to DPP-4 inhibitors.
在韩国进行的一项涉及20多万名患有2型糖尿病的成人的研究发现,服用普通糖尿病药物SGLT-2抑制剂(一种普通糖尿病药物)的人患痴呆症的风险降低了35%,而DPP-4抑制剂和另一种糖尿病药物则减少了35%。 A study in South Korea involving over 200,000 adults with type 2 diabetes found a 35% reduced risk of dementia for those taking SGLT-2 inhibitors, a common diabetes drug, compared to DPP-4 inhibitors, another diabetes medication. 研究表明,长时期使用SGLT-2药物的治疗可能会产生更显著的影响,使两年以上的治疗中患痴呆症的风险降低48%。 The study suggests that treatment with SGLT-2 drugs for longer durations could have more pronounced effects, with a 48% reduced risk of dementia for more than two years of treatment. 然而,需要随机控制审判来证实这些调查结果。 However, randomized controlled trials are needed to confirm these findings.